Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Callan JMB (NASDAQ: CJMB) has announced the pricing of its initial public offering of 1,280,000 shares at $4.00 per share, aiming to raise approximately $5.12 million in gross proceeds before deducting underwriting costs and offering expenses.
The company has granted underwriters a 45-day option to purchase up to an additional 192,000 shares at the public offering price. Trading is expected to begin on the Nasdaq Capital Market on February 5, 2025, under the ticker symbol ‘CJMB’, with the offering closing around February 6, 2025.
The net proceeds will be used for sales support, marketing, customer expansion, and general corporate purposes, including working capital. Alexander Capital is serving as the managing underwriter, with Paulson Investment Company as joint book-runner.
Callan JMB (NASDAQ: CJMB) ha annunciato la fissazione del prezzo per la sua offerta pubblica iniziale di 1.280.000 azioni a $4,00 per azione, con l’obiettivo di raccogliere circa $5,12 milioni in proventi lordi prima della deduzione dei costi di sottoscrizione e delle spese di offerta.
L’azienda ha concesso agli underwriter un’opzione di 45 giorni per acquistare fino a ulteriori 192.000 azioni al prezzo di offerta pubblica. Si prevede che le negoziazioni inizino sul Nasdaq Capital Market il 5 febbraio 2025, sotto il simbolo ‘CJMB’, con la chiusura dell’offerta prevista intorno al 6 febbraio 2025.
I proventi netti saranno utilizzati per il supporto alle vendite, marketing, espansione della clientela e scopi aziendali generali, inclusi i capitali di esercizio. Alexander Capital funge da underwriter principale, con Paulson Investment Company come co-book runner.
Callan JMB (NASDAQ: CJMB) ha anunciado el precio de su oferta pública inicial de 1.280.000 acciones a $4.00 por acción, con el objetivo de recaudar aproximadamente $5.12 millones en ingresos brutos antes de deducir los costos de suscripción y los gastos de oferta.
La compañía ha otorgado a los suscriptores una opción de 45 días para comprar hasta 192.000 acciones adicionales al precio de la oferta pública. Se espera que las operaciones comiencen en el Nasdaq Capital Market el 5 de febrero de 2025, bajo el símbolo ‘CJMB’, con el cierre de la oferta previsto alrededor del 6 de febrero de 2025.
Los ingresos netos se utilizarán para apoyo en ventas, marketing, expansión de clientes y propósitos corporativos generales, incluido el capital de trabajo. Alexander Capital está actuando como el suscriptor principal, con Paulson Investment Company como co-lider del libro.
Callan JMB (NASDAQ: CJMB)는 1,280,000 주의 초기 공모가를 $4.00 주당으로 가격을 책정했으며, 인수 비용 및 제공 비용을 공제하기 전 총 $5.12 백만을 모집하는 것을 목표로 하고 있습니다.
회사는 인수자에게 공모 가격으로 추가 192,000 주를 구매할 수 있는 45일 옵션을 부여했습니다. 거래는 2025년 2월 5일 나스닥 캐피탈 마켓에서 시작될 것으로 예상되며, 티커 심볼 ‘CJMB’로 거래될 예정이며, 공모는 2025년 2월 6일경에 마감될 것입니다.
순수익은 판매 지원, 마케팅, 고객 확장 및 일반 기업 목적(운전 자본 포함)으로 사용됩니다. Alexander Capital은 주관 인수자로, Paulson Investment Company는 공동 북런너로 활동하고 있습니다.
Callan JMB (NASDAQ: CJMB) a annoncé le prix de son introduction en bourse initiale de 1.280.000 actions à $4,00 par action, visant à lever environ $5,12 millions de produits bruts avant déduction des coûts de souscription et des frais d’offre.
La société a accordé aux souscripteurs une option de 45 jours pour acheter jusqu’à 192.000 actions supplémentaires au prix de l’offre publique. Le trading devrait commencer sur le Nasdaq Capital Market le 5 février 2025, sous le symbole ‘CJMB’, avec clôture de l’offre prévue autour du 6 février 2025.
Les produits nets seront utilisés pour le soutien aux ventes, le marketing, l’expansion de la clientèle et des fins d’entreprise générales, y compris le fonds de roulement. Alexander Capital agit en tant qu’underwriter principal, avec Paulson Investment Company comme co-book-runner.
Callan JMB (NASDAQ: CJMB) hat den Preis für sein Initial Public Offering von 1.280.000 Aktien zu $4,00 pro Aktie bekannt gegeben, mit dem Ziel, etwa $5,12 Millionen brutto zu erlösen, bevor die Underwriting-Kosten und Angebot expenses abgezogen werden.
Das Unternehmen hat den Underwritern eine 45-tägige Option eingeräumt, bis zu weitere 192.000 Aktien zum öffentlichen Angebotspreis zu kaufen. Der Handel wird voraussichtlich am 5. Februar 2025 an der Nasdaq Capital Market unter dem Tickersymbol ‘CJMB’ beginnen, wobei das Angebot voraussichtlich am 6. Februar 2025 endet.
Die Nettoerlöse werden für Vertriebsunterstützung, Marketing, Kundenausbau und allgemeine Unternehmenszwecke, einschließlich Betriebskapital, verwendet. Alexander Capital fungiert als leitender Underwriter, mit Paulson Investment Company als Co-Book-Runner.
Positive
- IPO provides $5.12M in new capital for business expansion
- Nasdaq Capital Market listing enhances company visibility and trading access
- Additional 192,000 shares option could provide extra capital if exercised
Negative
- Small IPO size might limit institutional investor interest
- Offering will cause immediate shareholder dilution
- Additional share option could cause further dilution if exercised
Insights
The pricing of Callan JMB’s IPO reveals several noteworthy aspects for investors. The $5.12M raise through 1.28M shares at $4.00 per share positions this as a micro-cap offering, which typically faces higher volatility and liquidity challenges. The modest size suggests a strategic decision to maintain greater control while accessing public markets, though it may limit institutional participation.
The planned use of proceeds focuses on sales support, marketing and customer expansion – a clear signal that Callan is prioritizing growth over infrastructure investment. This approach could accelerate market penetration in the expanding healthcare logistics sector, particularly valuable given the increasing complexity of medical supply chains and cold storage requirements.
The inclusion of a 45-day over-allotment option for 192,000 additional shares (15% of the base offering) provides flexibility to meet potential excess demand, though the small float size could lead to significant price volatility in early trading. The selection of Alexander Capital as lead underwriter, while not a bulge-bracket firm, aligns with the offering’s size and target market segment.
The timing of this IPO amid growing healthcare logistics demands positions Callan to potentially capitalize on industry tailwinds, particularly in cold chain logistics – a critical component for handling temperature-sensitive medical products. However, investors should note that micro-cap healthcare service providers often face significant challenges in scaling operations and competing with larger, established players.
SPRING BRANCH, Texas, Feb. 04, 2025 (GLOBE NEWSWIRE) — Callan JMB Inc. (NASDAQ: CJMB) (“Callan” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through exceptional fulfillment, storage, monitoring, and cold chain logistics services, today announced the pricing of its initial public offering (the “Offering”) of 1,280,000 shares (the “Shares”) of common stock (“Common Stock”) at an initial public offering price of $4.00 per Share for a total of approximately $5,120,000 of gross proceeds to the Company before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In addition, Callan has granted the underwriters a 45-day option to purchase, at the public offering price, up to an additional 192,000 shares of Common Stock at the public offering price, less the underwriting discounts and commissions.
The Shares are expected to begin trading on the Nasdaq Capital Market on February 5, 2025, under the ticker symbol “CJMB”. The Offering is expected to close on or about February 6, 2025, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds of the Offering primarily for sales support, marketing, customer expansion and general corporate purposes, including working capital.
Alexander Capital L.P. (“Alexander”) is the managing underwriter for the Offering, and Alexander and Paulson Investment Company, LLC are acting as joint book-runners for the Offering. Sichenzia Ross Ference Carmel LLP is serving as counsel to the Company, and Sullivan & Worcester LLP is serving as counsel to Alexander in connection with the Offering.
A registration statement on Form S-1, as amended (File No. 333-282879), relating to the Shares described above was filed with the U.S. Securities and Exchange Commission (“SEC”) and was declared effective on February 4, 2025. The Offering is being made only by means of a prospectus. A copy of the final prospectus relating to the Offering may be obtained, when available, from Alexander Capital, L.P., via email: info@alexandercapitallp.com, or by calling +1 (212) 687-5650, or by standard mail at Alexander Capital L.P., 10 Drs James Parker Blvd, Suite 202 Red Bank, New Jersey 07701, Attention: Equity Capital Markets. In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC’s website at www.sec.gov.
Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations, or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
About Callan JMB
Callan JMB is an integrative logistics company empowering the healthcare industry and emergency management agencies through exceptional fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer the Gold Standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging.
Forward Looking Statements:
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
212.896.1254
FAQ
What is the IPO price for Callan JMB (CJMB) shares?
Callan JMB (CJMB) has priced its IPO at $4.00 per share.
How many shares is Callan JMB (CJMB) offering in its IPO?
Callan JMB is offering 1,280,000 shares, with an additional 45-day option for underwriters to purchase up to 192,000 more shares.
When will CJMB stock begin trading on Nasdaq?
CJMB stock is expected to begin trading on the Nasdaq Capital Market on February 5, 2025.
How will Callan JMB use the IPO proceeds?
Callan JMB will use the net proceeds for sales support, marketing, customer expansion, and general corporate purposes, including working capital.
What is the total value of Callan JMB’s IPO?
The IPO is valued at approximately $5.12 million in gross proceeds before deducting underwriting costs and offering expenses.
Who are the underwriters for CJMB’s IPO?
Alexander Capital is the managing underwriter, with Alexander and Paulson Investment Company acting as joint book-runners for the offering.
